Ryan Watts Net Worth

The estimated Net Worth of Ryan J. Watts is at least $39.9 Million dollars as of 20 August 2024. Mr. Watts owns over 2,260 units of Denali Therapeutics Inc stock worth over $6,385,654 and over the last 7 years he sold DNLI stock worth over $28,567,248. In addition, he makes $4,978,610 as President, Chief Executive Officer, Co-Founder, and Director at Denali Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Watts DNLI stock SEC Form 4 insiders trading

Ryan has made over 47 trades of the Denali Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,260 units of DNLI stock worth $53,765 on 20 August 2024.

The largest trade he's ever made was selling 88,334 units of Denali Therapeutics Inc stock on 4 January 2021 worth over $6,621,517. On average, Ryan trades about 15,911 units every 39 days since 2017. As of 20 August 2024 he still owns at least 235,807 units of Denali Therapeutics Inc stock.

You can see the complete history of Mr. Watts stock trades at the bottom of the page.

Ryan Watts biography

Ryan J. Watts Ph.D. serves as President, Chief Executive Officer, Co-Founder, Director of the Company. He is one of our co-founders and has served as a member of our board of directors since March 2015 and as our President and Chief Executive Officer since August 2015. From March 2015 to August 2015, Dr. Watts acted as our interim President, Chief Scientific Officer and Head of Research and Development. Dr. Watts co-founded and joined Denali from Genentech, a biotechnology company, where he held various research and leadership roles of increasing responsibility between 2004 and 2015; from 2013 to February 2015, Dr. Watts served as Director of the Department of Neuroscience; from 2010 to 2013, Dr. Watts served as Associate Director of the Department of Neuroscience; and from 2004 to 2010, Dr. Watts led or served on numerous research and early development teams. In addition, Dr. Watts led Genentech’s blood-brain barrier team between 2009 and 2015, and he served as Chair of the Joint Research Committee with AC Immune between 2006 and 2010 (program currently in Phase 3) and between 2012 and 2014 (program currently in Phase 1). Dr. Watts received his Ph.D. in biological sciences from Stanford University and his B.S. in biology from the University of Utah. Dr. Watts has authored and co-authored more than 60 scientific papers and has been an invited peer reviewer i44n numerous publications including Cell, Nature Biotechnology, Nature Medicine, Neuron, Science and Science Translational Medicine.

What is the salary of Ryan Watts?

As the President, Chief Executive Officer, Co-Founder, and Director of Denali Therapeutics Inc, the total compensation of Ryan Watts at Denali Therapeutics Inc is $4,978,610. There are no executives at Denali Therapeutics Inc getting paid more.

How old is Ryan Watts?

Ryan Watts is 44, he's been the President, Chief Executive Officer, Co-Founder, and Director of Denali Therapeutics Inc since 2016. There are 18 older and 1 younger executives at Denali Therapeutics Inc. The oldest executive at Denali Therapeutics Inc is Vicki Sato, 71, who is the Independent Chairman of the Board.

What's Ryan Watts's mailing address?

Ryan's mailing address filed with the SEC is 151 Oyster Point Blvd, South San Francisco, CA 94080, USA.

Insiders trading at Denali Therapeutics Inc

Over the last 7 years, insiders at Denali Therapeutics Inc have traded over $438,930,443 worth of Denali Therapeutics Inc stock and bought 275,000 units worth $4,950,000 . The most active insiders traders include Llc Fmr, Douglas Kakdl, L.P.Crestlin..., and Jay T Flatley. On average, Denali Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,606,006. The most recent stock trade was executed by Vicki L Sato on 3 September 2024, trading 3,080 units of DNLI stock currently worth $77,000.

What does Denali Therapeutics Inc do?

denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).

Complete history of Mr. Watts stock trades at Denali Therapeutics Inc

Denali Therapeutics Inc executives and stock owners

Denali Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ryan Watts,
  President, Chief Executive Officer, Co-Founder, Director
• Steve Krognes,
  Chief Financial Officer, Treasurer
• Carole Ho,
  Chief Medical Officer, Head of Development
• Alexander Schuth,
  Co-Founder, Chief Operating Officer, Secretary
• Dr. Ryan J. Watts Ph.D.,
  Co-Founder, Pres, CEO & Director
• Steve Edward Krognes,
  CFO & Treasurer
• Dr. Carole Ho,
  Chief Medical Officer & Head of Devel.
• Dr. Alexander O. Schuth M.D.,
  Co-Founder, COO & Sec.
• Dr. Carole Ho M.D.,
  Chief Medical Officer & Head of Devel.
• Vicki Sato,
  Independent Chairman of the Board
• Marc Tessier-Lavignec,
  Independent Director
• Peter Klein,
  Independent Director
• David Schenkein,
  Independent Director
• Jay Flatley,
  Independent Director
• Douglas Cole,
  Independent Director
• Robert Nelsen,
  Independent Director
• Jennifer Cook,
  Independent Director
• Dr. Marc Tessier-Lavigne Ph.D.,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• Dr. Marc Tessier-Lavigne,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• Chris Walsh,
  Associate Gen. Counsel
• Dr. Laura Hansen,
  VP of Investor Relations
• Joe Lewcock,
  Chief Scientific Officer
• Dr. Dana Andersen,
  Chief Technical and Manufacturing Officer
• Tyler M. Nielsen,
  VP of Corp. Fin.
• Douglas Kakdl, L.P.Neuro Li...,
  
• Ventures Fund V, L.P.Afeyan...,
  
• Marc Tessier Lavigne,
  Director
• Ltd Fil,
  
• Llc Fmr,
  
• Venture Fund Viii, L.P.Arch...,
  
• Douglas K Neuro Line Partne...,
  
• Douglas Kakdl, L.P.Crestlin...,
  
• Nancy Thornberry,
  Director
• Erik Harris,
  Director